# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-053559
Filing Date
2022-04-29
Accepted
2022-04-29 16:11:29
Documents
6
Period of Report
2022-08-04

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm223528-1_def14a.htm | DEF 14A | 942814
2 | GRAPHIC | lg_avadel-4clr.jpg | GRAPHIC | 23951
3 | GRAPHIC | tm223528d1-pc_01proxybw.jpg | GRAPHIC | 842533
4 | GRAPHIC | tm223528d1-pc_02proxybw.jpg | GRAPHIC | 775585
5 | GRAPHIC | tm223528d1-px_01page4c.jpg | GRAPHIC | 676055
6 | GRAPHIC | tm223528d1-px_02page4c.jpg | GRAPHIC | 425649
| Complete submission text file | 0001104659-22-053559.txt |  | 4722213

Mailing Address 16640 CHESTERFIELD GROVE ROAD SUITE 200 CHESTERFIELD MO 63005
Business Address BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN DUBLIN L2 15 636-449-1830
AVADEL PHARMACEUTICALS PLC (Filer) CIK: 0001012477 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37977 | Film No.: 22875446
SIC: 2834 Pharmaceutical Preparations